Justin Kline

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12002585/publications.pdf

Version: 2024-02-01

81 papers	5,802 citations	185998 28 h-index	95083 68 g-index
81 all docs	81 docs citations	81 times ranked	9900 citing authors

#	Article	IF	Citations
1	Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8Î±+ dendritic cells. Journal of Experimental Medicine, 2011, 208, 2005-2016.	4.2	959
2	CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkinâ€™s Lymphoma. New England Journal of Medicine, 2018, 379, 1711-1721.	13.9	796
3	CD47 blockade triggers T cellâ€“mediated destruction of immunogenic tumors. Nature Medicine, 2015, 21, 1209-1215.	15.2	605
4	Immune resistance orchestrated by the tumor microenvironment. Immunological Reviews, 2006, 213, 131-145.	2.8	409
5	PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood, 2009, 114, 1545-1552.	0.6	354
6	Costimulatory and coinhibitory receptors in antiâ€tumor immunity. Immunological Reviews, 2009, 229, 126-144.	2.8	246
7	Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica, 2014, 99, 1373-1379.	1.7	213
8	Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood, 2011, 118, 6438-6445.	0.6	158
9	Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Current Opinion in Immunology, 2011, 23, 286-292.	2.4	134
10	STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Reports, 2016, 15, 2357-2366.	2.9	134
11	The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood, 2020, 135, 523-533.	0.6	134
12	Dendritic Cells Coordinate the Development and Homeostasis of Organ-Specific Regulatory T Cells. Immunity, 2016, 44, 847-859.	6.6	93
13	PDâ€1 regulates extrathymic regulatory Tâ€cell differentiation. European Journal of Immunology, 2014, 44, 2603-2616.	1.6	87
14	PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cellâ€“inflamed phenotype. Blood, 2019, 133, 2279-2290.	0.6	87
15	Mechanisms of Immune Tolerance in Leukemia and Lymphoma. Trends in Immunology, 2017, 38, 513-525.	2.9	86
16	Immune evasion in acute myeloid leukemia: current concepts and future directions. , 2013, 1, .		85
17	Leukemia cellâ€“targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood, 2014, 123, 15-25.	0.6	85
18	Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma. Clinical Cancer Research, 2008, 14, 3156-3167.	3.2	79

#	Article	IF	Citations
19	Homeostatic Proliferation as an Isolated Variable Reverses CD8+ T Cell Anergy and Promotes Tumor Rejection. Journal of Immunology, 2006, 177, 4521-4529.	0.4	75
20	Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity. Blood, 2018, 132, 92-92.	0.6	74
21	Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Advances, 2019, 3, 3488-3498.	2.5	62
22	CD40 ligation reverses T cell tolerance in acute myeloid leukemia. Journal of Clinical Investigation, 2013, 123, 1999-2010.	3.9	60
23	Immune profiles in primary squamous cell carcinoma of the head and neck. Oral Oncology, 2019, 96, 77-88.	0.8	57
24	Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Current Opinion in Investigational Drugs, 2010, 11, 1354-9.	2.3	48
25	Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation. Journal of Immunology, 2012, 188, 2630-2642.	0.4	45
26	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia, 2021, 35, 2672-2683.	3.3	45
27	Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing. Immunity, 2022, 55, 982-997.e8.	6.6	44
28	Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 913-921.	2.0	40
29	Targeting the Innate Immune System as Immunotherapy for Acute Myeloid Leukemia. Frontiers in Oncology, 2015, 5, 83.	1.3	33
30	Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia, 2022, 36, 994-1005.	3.3	33
31	Emerging role of checkpoint blockade therapy in lymphoma. Therapeutic Advances in Hematology, 2017, 8, 81-90.	1.1	32
32	Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia. OncoImmunology, 2017, 6, e1278332.	2.1	29
33	PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation. , 2017, 5, 11.		29
34	Highly clonal regulatory T-cell population in follicular lymphoma â€“ inverse correlation with the diversity of CD8⁺T cells. OncoImmunology, 2015, 4, e1002728.	2.1	26
35	Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leukemia and Lymphoma, 2013, 54, 1242-1249.	0.6	23
36	CD8Î±+ Dendritic Cells Dictate Leukemia-Specific CD8+ T Cell Fates. Journal of Immunology, 2018, 201, 3759-3769.	0.4	23

#	Article	IF	Citations
37	T-LAK cell-originated protein kinase presents a novel therapeutic target inFLT3-ITD mutated acute myeloid leukemia. Oncotarget, 2015, 6, 33410-33425.	0.8	22
38	Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. Experimental Hematology and Oncology, 2019, 8, 1.	2.0	21
39	Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2016, 22, 1065-1072.	2.0	20
40	Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 359-365.	2.0	20
41	Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1025-1027.	2.0	20
42	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biology of Blood and Marrow Transplantation, 2018, 24, 997-1004.	2.0	18
43	Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient Obesity. Cancer Immunology Research, 2021, 9, 214-226.	1.6	18
44	No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. Journal of Oncology Practice, 2016, 12, e901-e911.	2.5	13
45	Update on checkpoint blockade therapy for lymphoma. , 2015, 3, 33.		11
46	Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. , 2020, 8, e000286.		11
47	Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplantation, 2020, 55, 1161-1168.	1.3	11
48	Pembrolizumab for the Treatment of Disease Relapse Following Allogeneic Hematopoietic Cell Transplantation. Blood, 2018, 132, 3415-3415.	0.6	11
49	Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leukemia and Lymphoma, 2016, 57, 1807-1813.	0.6	9
50	Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes. Blood, 2019, 134, 924-924.	0.6	8
51	MYC â€" a thorn in the side of cancer immunity. Cell Research, 2016, 26, 639-640.	5.7	7
52	Negligible Role for Deletion Mediated by cDC1 in CD8+ T Cell Tolerance. Journal of Immunology, 2019, 202, 2628-2635.	0.4	6
53	Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and SÃ©zary syndrome. British Journal of Haematology, 2019, 186, 377-379.	1.2	6
54	Procalcitonin As a Potential Biomarker for Differentiating Bacterial Infectious Fevers from Cytokine Release Syndrome. Blood, 2018, 132, 4216-4216.	0.6	5

#	Article	IF	Citations
55	Nelarabine in the treatment of refractory T-cell malignant diseases. Expert Opinion on Pharmacotherapy, 2006, 7, 1791-1799.	0.9	4
56	Peripheral T-cell tolerance in hosts with acute myeloid leukemia. OncoImmunology, 2013, 2, e25445.	2.1	4
57	Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 2019, 60, 629-638.	0.6	4
58	Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood, 2021, 137, 3454-3459.	0.6	4
59	PD-L1 Gene Alterations Identify a Unique Subset of Diffuse Large B Cell Lymphoma That Harbors a T Cell Inflamed Phenotype. Blood, 2018, 132, 673-673.	0.6	4
60	Geriatric Assessment (GA) to Predict Survival in Older Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients. Biology of Blood and Marrow Transplantation, 2014, 20, S39-S40.	2.0	3
61	The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672). Blood, 2019, 134, 1591-1591.	0.6	3
62	Divergent fates of antigen-specific CD8+ TÂcell clones in mice with acute leukemia. Cell Reports, 2021, 37, 109991.	2.9	3
63	Will changing the face of WT1 make it more attractive to T cells?. Leukemia and Lymphoma, 2009, 50, 156-157.	0.6	2
64	Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 1956-1956.	0.6	2
65	Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL. Blood, 2019, 134, 391-391.	0.6	2
66	Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309. Blood, 2016, 128, 4147-4147.	0.6	2
67	Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors. Blood, 2008, 112, 3015-3015.	0.6	1
68	A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADEÂ®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL. Blood, 2011, 118, 1646-1646.	0.6	1
69	Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies. Blood, 2011, 118, 830-830.	0.6	1
70	Comorbidity from Solid Tumor or Hematologic Malignancy Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) May Both Increase Non-Relapse Mortality. Blood, 2016, 128, 5844-5844.	0.6	1
71	Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas. Blood, 2020, 136, 43-44.	0.6	1
72	Macrophage Activation By Dual PI3K-Î´/Î³ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL. Blood, 2020, 136, 40-40.	0.6	1

#	Article	IF	Citations
73	Conditioning with Fludarabine (Flu)-Alkylator Is More Effective Cytoreduction Than Cyclophosphamide-Total Body Irradiation (Cy/TBI) for Refractory, Progressive Chronic Lymphatic Leukemia (CLL).. Blood, 2004, 104, 5045-5045.	0.6	0
74	Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study. Blood, 2011, 118, 1948-1948.	0.6	0
75	Selection and Monitoring of Patients for Immunotherapy (Peptide Vaccines). , 2015, , 63-84.		0
76	Excellent Clinical Outcome for Relapsed and Refractory Lymphoma Patients with Haplo-Cord Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 3496-3496.	0.6	0
77	Development of Acute Myeloid Leukemia Cell Membrane Coated Nanoparticles (AMCNPs) for Cancer Vaccination Immunotherapy. Blood, 2018, 132, 4062-4062.	0.6	0
78	Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS. Blood, 2019, 134, 3324-3324.	0.6	0
79	A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma. Blood, 2021, 138, 2420-2420.	0.6	0
80	Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8+ T Cell Population with a Cytotoxic Phenotype. Blood, 2020, 136, 40-41.	0.6	0
81	Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT). Blood, 2020, 136, 39-40.	0.6	0